logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9133145 B1

PDFFull Text
Date of Patent:
Sep. 15, 2015

Filed:

Mar. 01, 2013

Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Applicant:

Abbvie Inc., North Chicago, IL (US);

Inventors:

R. Scott Bitner, Pleasant Prairie, WI (US);

Kaitlin E. Browman, Deerfield, IL (US);

Michael E. Brune, Mundelein, IL (US);

Steven X. Fung, Mount Prospect, IL (US);

Peer B. Jacobson, Libertyville, IL (US);

Lynne E. Rueter, Round Lake Beach, IL (US);

Marina I. Strakhova, Vernon Hills, IL (US);

Jiahong Wang, Lake Bluff, IL (US);

James T. Link, Stanford, CA (US);

Yixian Chen, Glenview, IL (US);

Hwan-soo Jae, Glencoe, IL (US);

Jyoti R. Patel, Libertyville, IL (US);

Marina A. Pliushchev, Vernon Hills, IL (US);

Jeffrey J. Rohde, Evanston, IL (US);

Qi Shuai, Dekalb, IL (US);

Bryan K. Sorensen, Antioch, IL (US);

Martin Winn, Deerfield, IL (US);

Dariusz Wodka, Monmouth Junction, NJ (US);

Hong Yong, Libertyville, IL (US);

Assignee:

AbbVie Inc., North Chicago, IL (US);

Attorneys:

Lisa V. Mueller

Michael Best & Friedrich LLP

Primary Examiner:

Kamal Saeed

Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61K 31/55 (2006.01); C07D 295/155 (2006.01); C07D 205/04 (2006.01); C07D 207/12 (2006.01); C07D 209/44 (2006.01); C07D 211/42 (2006.01); C07D 213/72 (2006.01); C07D 231/12 (2006.01); C07D 239/42 (2006.01); A61K 31/5375 (2006.01); C07D 277/82 (2006.01); C07D 295/125 (2006.01); C07D 307/68 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 413/12 (2006.01); C07D 487/04 (2006.01); C07D 491/056 (2006.01);
U.S. Cl.
CPC ...
C07D 295/155 (2013.01); A61K 31/496 (2013.01); A61K 31/5375 (2013.01); A61K 31/55 (2013.01); C07D 205/04 (2013.01); C07D 207/12 (2013.01); C07D 209/44 (2013.01); C07D 211/42 (2013.01); C07D 213/72 (2013.01); C07D 231/12 (2013.01); C07D 239/42 (2013.01); C07D 277/82 (2013.01); C07D 295/125 (2013.01); C07D 307/68 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 413/12 (2013.01); C07D 487/04 (2013.01); C07D 491/056 (2013.01);
Abstract

The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Find Patent Forward Citations

Loading…